Nutriband Has Completed The Market Assessment And Commercialization Strategy For Aversa Buprenorphine, An Abuse-deterrent Buprenorphine Transdermal System; Aversa Buprenorphine Peak Annual US Sales Is Expected To Reach $70M-130M
Portfolio Pulse from Benzinga Newsdesk
Nutriband has completed the market assessment and commercialization strategy for Aversa Buprenorphine, an abuse-deterrent Buprenorphine transdermal system. The peak annual US sales for Aversa Buprenorphine is expected to reach $70M-130M.
October 11, 2023 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nutriband's completion of the market assessment and commercialization strategy for Aversa Buprenorphine could potentially boost its revenues, with peak annual US sales expected to reach $70M-130M.
The completion of the market assessment and commercialization strategy for Aversa Buprenorphine indicates that Nutriband is ready to launch the product in the market. The projected peak annual US sales of $70M-130M suggest a significant potential increase in Nutriband's revenues, which could positively impact the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100